Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2018 1
2019 1
2020 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Management of multiple sclerosis patients in central European countries: current needs and potential solutions.
Berger T, Adamczyk-Sowa M, Csépány T, Fazekas F, Hojs Fabjan T, Horáková D, Illes Z, Klimová E, Leutmezer F, Rejdak K, Rozsa C, Šega Jazbec S, Szilasiová J, Turčáni P, Vachová M, Vécsei L, Havrdová E. Berger T, et al. Ther Adv Neurol Disord. 2018 Feb 22;11:1756286418759189. doi: 10.1177/1756286418759189. eCollection 2018. Ther Adv Neurol Disord. 2018. PMID: 29511382 Free PMC article. Review.
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.
Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, Havrdová E, Hillert J, Hohlfeld R, Kremenchutzky M, Lyon-Caen O, Miller A, Pozzilli C, Ravnborg M, Saida T, Sindic C, Vass K, Clifford DB, Hauser S, Major EO, O'Connor PW, Weiner HL, Clanet M, Gold R, Hirsch HH, Radü EW, Sørensen PS, King J. Kappos L, et al. Lancet Neurol. 2011 Aug;10(8):745-58. doi: 10.1016/S1474-4422(11)70149-1. Lancet Neurol. 2011. PMID: 21777829 Free article. Review.
In this Review, we revisit and update previous recommendations on natalizumab for treatment of patients with RRMS, based on additional long-term follow-up of clinical studies and post-marketing observations, including appropriate patient selection and management recommenda …
In this Review, we revisit and update previous recommendations on natalizumab for treatment of patients with RRMS, based on additional long- …
Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease.
Berger T, Adamczyk-Sowa M, Csépány T, Fazekas F, Fabjan TH, Horáková D, Ledinek AH, Illes Z, Kobelt G, Jazbec SŠ, Klímová E, Leutmezer F, Rejdak K, Rozsa C, Sellner J, Selmaj K, Štouracˇ P, Szilasiová J, Turcˇáni P, Vachová M, Vanecková M, Vécsei L, Havrdová EK. Berger T, et al. Ther Adv Neurol Disord. 2020 Dec 7;13:1756286420975223. doi: 10.1177/1756286420975223. eCollection 2020. Ther Adv Neurol Disord. 2020. PMID: 33335562 Free PMC article. Review.
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
Spelman T, Herring WL, Zhang Y, Tempest M, Pearson I, Freudensprung U, Acosta C, Dort T, Hyde R, Havrdova E, Horakova D, Trojano M, De Luca G, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Alroughani R, Pucci E, Granella F, Lechner-Scott J, Sola P, Ferraro D, Grand'Maison F, Terzi M, Rozsa C, Boz C, Hupperts R, Van Pesch V, Oreja-Guevara C, van der Walt A, Jokubaitis VG, Kalincik T, Butzkueven H; MSBase Investigators. Spelman T, et al. Pharmacoeconomics. 2022 Mar;40(3):323-339. doi: 10.1007/s40273-021-01106-6. Epub 2021 Dec 18. Pharmacoeconomics. 2022. PMID: 34921350 Free PMC article.
Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.
Phelps R, Winston JA, Wynn D, Habek M, Hartung HP, Havrdová EK, Markowitz GS, Margolin DH, Rodriguez CE, Baker DP, Coles AJ. Phelps R, et al. Mult Scler. 2019 Aug;25(9):1273-1288. doi: 10.1177/1352458519841829. Epub 2019 Apr 15. Mult Scler. 2019. PMID: 30986126 Free PMC article.
METHODS: Cases were identified from safety monitoring within the alemtuzumab relapsing-remitting multiple sclerosis (RRMS) clinical development program (CDP) or post-marketing, or following off-label use. RESULTS: As of 16 June 2017, 16 autoimmune nephropathies have occurr …
METHODS: Cases were identified from safety monitoring within the alemtuzumab relapsing-remitting multiple sclerosis (RRMS) clinical developm …
Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome.
Meyniel C, Spelman T, Jokubaitis VG, Trojano M, Izquierdo G, Grand'Maison F, Oreja-Guevara C, Boz C, Lugaresi A, Girard M, Grammond P, Iuliano G, Fiol M, Cabrera-Gomez JA, Fernandez-Bolanos R, Giuliani G, Lechner-Scott J, Cristiano E, Herbert J, Petkovska-Boskova T, Bergamaschi R, van Pesch V, Moore F, Vella N, Slee M, Santiago V, Barnett M, Havrdova E, Young C, Sirbu CA, Tanner M, Rutherford M, Butzkueven H; MSBasis Study Group. Meyniel C, et al. PLoS One. 2012;7(6):e38661. doi: 10.1371/journal.pone.0038661. Epub 2012 Jun 29. PLoS One. 2012. PMID: 22768046 Free PMC article.